Martin L Miller
Overview
Explore the profile of Martin L Miller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
7974
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Memon D, Schoenfeld A, Ye D, Fromm G, Rizvi H, Zhang X, et al.
Cancer Cell
. 2024 Jan;
42(2):209-224.e9.
PMID: 38215748
Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired...
2.
Kehrloesser S, Cast O, Elliott T, Ernst R, Machel A, Chen J, et al.
PNAS Nexus
. 2023 Apr;
2(4):pgad107.
PMID: 37091541
The ability to assign cellular origin to low-abundance secreted factors in extracellular vesicles (EVs) would greatly facilitate the analysis of paracrine-mediated signaling. Here, we report a method, named selective isolation...
3.
Bou-Tayeh B, Miller M
Immunity
. 2021 Jun;
54(6):1107-1109.
PMID: 34107269
The determinants of T cell infiltration in tumors remain largely unknown. In a recent issue of Cancer Cell, Hornburg et al. use single-cell RNA sequencing to characterize the cellular compartments...
4.
Memon D, Gill M, Papachristou E, Ochoa D, DSantos C, Miller M, et al.
Cell Rep
. 2021 May;
35(7):109155.
PMID: 34010657
Somatic DNA copy number variations (CNVs) are prevalent in cancer and can drive cancer progression, albeit with often uncharacterized roles in altering cell signaling states. Here, we integrate genomic and...
5.
Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton J, Curbishley S, et al.
Br J Cancer
. 2021 Mar;
124(11):1759-1776.
PMID: 33782566
Cancer is a leading cause of death worldwide and, despite new targeted therapies and immunotherapies, many patients with advanced-stage- or high-risk cancers still die, owing to metastatic disease. Adoptive T-cell...
6.
Veeraraghavan H, Vargas H, Jimenez-Sanchez A, Micco M, Mema E, Lakhman Y, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33212885
Develop an integrated intra-site and inter-site radiomics-clinical-genomic marker of high grade serous ovarian cancer (HGSOC) outcomes and explore the biological basis of radiomics with respect to molecular signaling pathways and...
7.
Rabbie R, Ansari-Pour N, Cast O, Lau D, Scott F, Welsh S, et al.
Nat Commun
. 2020 Aug;
11(1):4306.
PMID: 32855398
Metastatic melanoma carries a poor prognosis despite modern systemic therapies. Understanding the evolution of the disease could help inform patient management. Through whole-genome sequencing of 13 melanoma metastases sampled at...
8.
Jimenez-Sanchez A, Cybulska P, Mager K, Koplev S, Cast O, Couturier D, et al.
Nat Genet
. 2020 Jun;
52(6):582-593.
PMID: 32483290
In metastatic cancer, the degree of heterogeneity of the tumor microenvironment (TME) and its molecular underpinnings remain largely unstudied. To characterize the tumor-immune interface at baseline and during neoadjuvant chemotherapy...
9.
Van den Eynden J, Jimenez-Sanchez A, Miller M, Larsson E
Nat Genet
. 2019 Nov;
51(12):1741-1748.
PMID: 31768072
Somatic mutations can result in the formation of neoantigens, immunogenic peptides that are presented on the tumor cell surface by HLA molecules. These mutations are expected to be under negative...
10.
Jimenez-Sanchez A, Cast O, Miller M
Cancer Res
. 2019 Oct;
79(24):6238-6246.
PMID: 31641033
Various computational approaches have been developed for estimating the relative abundance of different cell types in the tumor microenvironment (TME) using bulk tumor RNA data. However, a comprehensive comparison across...